Key result
Studies with a quality score ≥0.60 were more likely to identify a therapeutic window for haloperidol compared to lower-quality studies.
Why the study?
Is there a relationship between haloperidol blood levels and clinical efficacy, and is this relationship dependent on study quality?
Systematic Review (n=33)
Is there a relationship between haloperidol blood levels and clinical efficacy, and is this relationship dependent on study quality?
Answers are grounded in this paper and cite their sources.
Higher quality studies are significantly more likely to identify a therapeutic window for haloperidol, suggesting that an upper limit for its clinical efficacy exists.
There are now more than 50 studies concerning neuroleptic blood levels and clinical outcome relationships. Haloperidol, the most studied, is the only antipsychotic permitting some conclusions. A number of authors suggest that the striking lack of agreement between different studies results from heterogeneity of their quality. Here, we have used a scoring system for assessing the quality of those studies. According to this system, none (0/14) of the studies having a score < 0.60 was able to show a therapeutic window, as compared to 53% (10/19) of those having a score > or = 0.60 (p = 0.002, Fisher exact test). Also, the studies able to identify the presence of a therapeutic window during haloperidol treatment were those having sample size > 20 (p = 0.06) and those whose patients were treated with fixed doses (p = 0.02). The diagnosis of schizophrenia in the studies seems not to be an exclusive condition, as compared with those also including schizophreniform and schizoaffective disorders (p = 0.12). Our qualitative analysis of haloperidol blood level publications seem to indicate that an upper limit may exist for haloperidol efficacy; values above this limit seem not to provide any supplementary clinical improvement and may even reduce therapeutic effect.
No takes yet. Share an insight, caveat, or question.
Oliveira et al. (1995) conducted a systematic review in Schizophrenia, schizophreniform, and schizoaffective disorders (n=33). Study quality score ≥ 0.60 vs. Study quality score < 0.60 was evaluated on Ability to show a therapeutic window (p=0.002). Studies with a quality score ≥0.60 were more likely to identify a therapeutic window for haloperidol compared to lower-quality studies.
Synapse has enriched 10 related papers. Consider them for comparative context: